• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Anebulo Pharmaceuticals Inc.

    2/14/25 4:32:39 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANEB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ANEBULO PHARMACEUTICALS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    034569103

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    034569103


    1Names of Reporting Persons

    Nantahala Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,547,398.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,547,398.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,547,398.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.63 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    034569103


    1Names of Reporting Persons

    Wilmot B. Harkey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,547,398.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,547,398.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,547,398.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.63 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    034569103


    1Names of Reporting Persons

    Daniel Mack
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,547,398.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,547,398.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,547,398.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.63 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ANEBULO PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    1017 Ranch Road 620 South SUITE 107 LAKEWAY, TEXAS, 78734
    Item 2. 
    (a)Name of person filing:

    (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    130 Main St. 2nd Floor, New Canaan, Connecticut 06840
    (c)Citizenship:

    (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    034569103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of December 31, 2024, Nantahala may be deemed to be the beneficial owner of 3,547,398 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 3,547,398 Shares includes 511,073 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
    (b)Percent of class:

    As of December 31, 2024, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 8.63% (2) Wilmot B. Harkey: 8.63% (3) Daniel Mack: 8.63%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (ii) Shared power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 3,547,398 Shares. (2) Wilmot B. Harkey: 3,547,398 Shares. (3) Daniel Mack: 3,547,398 Shares.

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 3,547,398 Shares. (2) Wilmot B. Harkey: 3,547,398 Shares. (3) Daniel Mack: 3,547,398 Shares.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Nantahala Capital Management, LLC
     
    Signature:/s/ Taki Vasilakis
    Name/Title:Taki Vasilakis / Chief Compliance Officer
    Date:02/14/2025
     
    Wilmot B. Harkey
     
    Signature:/s/ Wilmot B. Harkey
    Name/Title:Wilmot B. Harkey
    Date:02/14/2025
     
    Daniel Mack
     
    Signature:/s/ Daniel Mack
    Name/Title:Daniel Mack
    Date:02/14/2025
    Get the next $ANEB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANEB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANEB
    SEC Filings

    View All

    SEC Form 25 filed by Anebulo Pharmaceuticals Inc.

    25 - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

    2/17/26 4:52:16 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Anebulo Pharmaceuticals Inc.

    SCHEDULE 13G/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

    2/13/26 5:00:58 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Anebulo Pharmaceuticals Inc.

    10-Q - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

    2/12/26 4:30:45 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2025, and recent updates. Second Quarter Fiscal Year 2026 and Subsequent Highlights: On February 6, 2026, Anebulo announced that the Company's board of directors (the "Board") approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission ("SEC") in order to t

    2/12/26 4:15:00 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that the Company's board of directors (the "Board") has approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission ("SEC") in order to terminate and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Simultaneously with this announcement, Anebulo notified Na

    2/6/26 9:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Final Results of Tender Offer

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share ("Common Stock"), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the final count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer, a total of 4,907,881 shares of Common Stock were properly tendered and not properly withdrawn. The tender offer was oversubscribed. In

    1/29/26 9:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lawler Joseph F.

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    4/7/25 9:41:39 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Shah Bimal R.

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    4/7/25 9:41:38 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Cundy Kenneth C

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    4/7/25 9:41:37 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director English Aron R. bought $10,000,000 worth of shares (10,101,010 units at $0.99) (SEC Form 4)

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    12/26/24 4:15:08 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Financials

    Live finance-specific insights

    View All

    Ligand Reports Third Quarter 2023 Financial Results

    Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

    11/8/23 4:01:00 PM ET
    $AMGN
    $ANEB
    $JAZZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ligand Reports First Quarter 2023 Financial Results

    2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

    5/4/23 4:01:00 PM ET
    $ANEB
    $LGND
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

    Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the "Company" or "Anebulo"), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of

    7/5/22 6:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Leadership Updates

    Live Leadership Updates

    View All

    Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio

    10/6/23 4:06:00 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

    Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction, today announced the appointment of Sandra Gardiner as the Company's acting chief financial officer.  Ms. Gardiner joins Anebul

    3/8/23 8:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board. "We are very pleased to welcome Nat to the Anebulo Board," said Simon Allen, Chief Executive Officer of Anebulo. "Nat's deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001." Dr. Calloway is an analys

    11/1/22 4:00:00 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care